Figure 1From: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy Percent change from baseline in sum of longest diameter of target lesions. Red: Progressive Disease, Green: Progressive Disease due to development of new metastatic lesions, Blue: Stable Disease. Two patients did not receive post-treatment imaging due to rapid clinical progression of disease.Back to article page